Interasma Global Asthma Association

GAA-Interasma Scientific Activity Survey

supported by an unrestricted grant from Chiesi Italy s.p.a.

Survey Form

    1. A 17% exacerbation reduction using triple therapy vs ICS plus LABA has been showed (Lisa HY Kim et al, JAMA 2021 ref. GINA 2022). How much do you agree in considering 17% of reduction a remarkable result?
    Strongly disagree Fully agree

    2. Do you agree with GINA statement that triple therapy modestly improve lung function?
    Strongly disagree Fully agree

    3. How often do you consider medium ICS dose triple therapy for your patients?
    Never Always

    4. Do you agree triple therapy is a second option after having reached high dose ICS-LABA?
    Strongly disagree Fully agree

    5. How much do you agree optimizing inhalation therapy should always be attempted before considering biologics?
    Strongly disagree Fully agree

    6. Biologics should always be given with high dose ICS-LABA
    Strongly disagree Fully agree

    7. Biologics should always be given with triple therapy
    Strongly disagree Fully agree

    8. Have you ever considered stepping down from high dose triple therapy or high ICS-LABA to medium dose triple therapy?
    Never Always

    8. Have you ever considered stepping down from high dose triple therapy to high dose of ICS/LABA?
    Never Always

    9. In general, do you think GINA’s treatment algorithm can be easily transferred to clinical practice?
    Strongly disagree Fully agree

    10. How often do you check persistent airflow limitation in your current practice for prescribing the treatment?
    Never Always

    11. How much do you consider airflow limitation as a treatable trait to base treatment choice in your current practice in asthma?
    No importance Very high importance

    12. Do you agree persistent airflow limitation can be a strong predictor of better results with triple therapy?
    Strongly disagree Fully agree

    13. Do you agree higher reversibility can be a strong predictor of better results with triple therapy?
    Strongly disagree Fully agree

    14. Do you agree severe obstrution (FEV1 <80%) can be a treatable trait to be addressed by triple therapy?
    Strongly disagree Fully agree

    15. Triple therapy is still an under-used treatment in your country or local reality
    Strongly disagree Fully agree

    16. Would you consider different phenotypes for the use of triple therapy?
    Never Always

    17. According to the available evidence, how do you consider eosinophilic inflammation to guide the adoption of triple therapy?
    No importance Very high importance

    18. What are the clinical features (treatable traits) you consider more predictive of good response to triple therapy?

    19. How do you consider the availability of triple therapy in a single inhaler?
    No importance Very high importance